Kidney transplantation is the preferred treatment for patients with end-stage kidney disease,
because it prolongs survival and improves quality of life. Allograft biopsy is the gold standard …

Objectives Galactose-deficient IgA1 (Gd-IgA1) is a critical effector molecule in the
pathogenesis of IgA nephropathy (IgAN), a leading renal disease without noninvasive …

Background IgA nephropathy may recur in patients receiving kidney transplantation due to
IgA nephropathy induced renal failure. The risk factors for recurrence are still at issue. The …

Abstract Background Immunoglobulin A nephropathy (IgAN) is a main cause of end stage
renal disease (ESRD). Many IgAN patients with ESRD accept kidney allograft for renal …

IgA nephropathy (IgAN) is the most common form of glomerulonephritis worldwide. IgAN
progresses to end-stage kidney disease in 20–40% of patients within 20 years of diagnosis …

Recurrent glomerulonephritis after renal transplantation is the third most common cause of
allograft loss, the most frequent of which is associated with IgA nephropathy (IgAN). This …

IgA nephropathy is the commonest pattern of primary glomerular disease in the world, with
high rates of progression to kidney failure. As IgA nephropathy commonly causes kidney …

A 39-year-old male kidney transplant recipient with Down syndrome (DS) was admitted to
our hospital for biopsy. He had proteinuria at age 9, was diagnosed with immunoglobulin A …

Background Allogeneic kidney transplantation (KT) is an effective treatment for end-stage
renal disease caused by progressing immunoglobulin A nephropathy (IgAN). However, the …

Immunoglobulin A (IgA) nephropathy (IgAN), the most common primary glomerulonephritis
worldwide, frequently leads to end-stage renal disease, which requires renal replacement …